DNA Biomed (Israel) Performance
| DNA Stock | ILS 88.60 1.60 1.84% |
On a scale of 0 to 100, DNA Biomed holds a performance score of 10. The firm owns a Beta (Systematic Risk) of 0.78, which means possible diversification benefits within a given portfolio. As returns on the market increase, DNA Biomed's returns are expected to increase less than the market. However, during the bear market, the loss of holding DNA Biomed is expected to be smaller as well. Please check DNA Biomed's semi deviation, sortino ratio, semi variance, as well as the relationship between the standard deviation and value at risk , to make a quick decision on whether DNA Biomed's current price history will revert.
Risk-Adjusted Performance
10 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in DNA Biomed Solns are ranked lower than 10 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak basic indicators, DNA Biomed sustained solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 42 K | |
| Total Cashflows From Investing Activities | -1.4 M |
DNA |
DNA Biomed Relative Risk vs. Return Landscape
If you would invest 6,820 in DNA Biomed Solns on August 27, 2024 and sell it today you would earn a total of 2,040 from holding DNA Biomed Solns or generate 29.91% return on investment over 90 days. DNA Biomed Solns is generating 0.6875% of daily returns assuming 4.9641% volatility of returns over the 90 days investment horizon. Simply put, 44% of all stocks have less volatile historical return distribution than DNA Biomed, and 87% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
DNA Biomed Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for DNA Biomed's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as DNA Biomed Solns, and traders can use it to determine the average amount a DNA Biomed's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1385
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | DNA | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 4.96 actual daily | 44 56% of assets are more volatile |
Expected Return
| 0.69 actual daily | 13 87% of assets have higher returns |
Risk-Adjusted Return
| 0.14 actual daily | 10 90% of assets perform better |
Based on monthly moving average DNA Biomed is performing at about 10% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of DNA Biomed by adding it to a well-diversified portfolio.
DNA Biomed Fundamentals Growth
DNA Stock prices reflect investors' perceptions of the future prospects and financial health of DNA Biomed, and DNA Biomed fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on DNA Stock performance.
| Return On Equity | -0.25 | |||
| Return On Asset | -0.0375 | |||
| Current Valuation | 59.57 M | |||
| Shares Outstanding | 123.16 M | |||
| Price To Earning | 22.59 X | |||
| Price To Book | 0.95 X | |||
| EBITDA | 18.42 M | |||
| Cash And Equivalents | 492 K | |||
| Book Value Per Share | 0.79 X | |||
| Cash Flow From Operations | (2.33 M) | |||
| Earnings Per Share | 0.21 X | |||
| Total Asset | 54.62 M | |||
| Retained Earnings | (139 M) | |||
| Current Asset | 26 M | |||
| Current Liabilities | 8 M | |||
About DNA Biomed Performance
By analyzing DNA Biomed's fundamental ratios, stakeholders can gain valuable insights into DNA Biomed's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if DNA Biomed has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if DNA Biomed has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
D.N.A Biomedical Solutions Ltd. develops and commercializes laser spectrometry-based trace detection systems in Israel. D.N.A Biomedical Solutions Ltd. was founded in 2004 and is based in Ramat Gan, Israel. D N operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange.Things to note about DNA Biomed Solns performance evaluation
Checking the ongoing alerts about DNA Biomed for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for DNA Biomed Solns help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| DNA Biomed Solns appears to be risky and price may revert if volatility continues | |
| The company has a current ratio of 0.03, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist DNA Biomed until it has trouble settling it off, either with new capital or with free cash flow. So, DNA Biomed's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like DNA Biomed Solns sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for DNA to invest in growth at high rates of return. When we think about DNA Biomed's use of debt, we should always consider it together with cash and equity. | |
| DNA Biomed Solns has accumulated about 492 K in cash with (2.33 M) of positive cash flow from operations. | |
| Roughly 55.0% of the company shares are held by company insiders |
- Analyzing DNA Biomed's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether DNA Biomed's stock is overvalued or undervalued compared to its peers.
- Examining DNA Biomed's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating DNA Biomed's management team can have a significant impact on its success or failure. Reviewing the track record and experience of DNA Biomed's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of DNA Biomed's stock. These opinions can provide insight into DNA Biomed's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for DNA Stock analysis
When running DNA Biomed's price analysis, check to measure DNA Biomed's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy DNA Biomed is operating at the current time. Most of DNA Biomed's value examination focuses on studying past and present price action to predict the probability of DNA Biomed's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move DNA Biomed's price. Additionally, you may evaluate how the addition of DNA Biomed to your portfolios can decrease your overall portfolio volatility.
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments |